Hematology

CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed more work to be done with CAR T-cell therapies.

Mustang Bio presented data on MB-106 at the 2022 EHA Congress.

Among treated patients, 42% achieved 5-year event free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Updated date from the B-LIEVE study is expected in the second half of 2022 and first half of 2023.

GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.

The CD-19 CAR T-cell therapy is developed using Curocell’s OVISTM platform.

Results from the CLIMB THAL-111 and CLIMB SCD-121 trials were presented at the EHA 2022 Congress.

Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.

Participants in the trial achieved a sustained response and experienced low-grade toxicity.

A phase 2 clinical trial evaluating a T-cell memory enriched anti-CD30 CAR-T is now underway.

As of the data cutoff, 3 of 5 treated participants remain in complete response.

Statistically significant differences were seen in global health status, pain, and fatigue.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee again voted in favor of the risk-benefit of bluebird bio's gene therapy candidate.

Review top news and interview highlights from the week ending June 10, 2022.

Three of 6 patients have an ongoing response.

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed positive data seen with tisa-cel, liso-cel, ide-cel, cilta-cel, and brexu-cel.

Data from a phase 1/2a study showed notable response rates in patients who had received a median of 5 prior lines of therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.

100% overall response and complete response rates were seen in patients treated with prior CD19 CAR T-cell therapy.

Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.

The findings suggest that less disadvantaged patients with high disease burden may have greater ability to advocate for CAR T-cell therapy.

69% of patients followed up for at least 1 year continue to have an ongoing response.